Effect of a new formulation of micronized and ultramicronized N-palmitoylethanolamine in a tibia fracture mouse model of complex regional pain syndrome by Fusco, Roberta et al.
RESEARCH ARTICLE
Effect of a new formulation of micronized and
ultramicronized N-palmitoylethanolamine in a
tibia fracture mouse model of complex
regional pain syndrome
Roberta Fusco1☯, Enrico Gugliandolo1☯, Michela Campolo1‡, Maurizio Evangelista2‡,
Rosanna Di Paola1‡*, Salvatore Cuzzocrea1,3‡*
1 Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina,
Messina, Italy, 2 Institute of Anaesthesiology and Reanimation, Catholic University of the Sacred Heart,
Rome, Italy, 3 Department of Pharmacological and Physiological Science, Saint Louis University School of
Medicine, St. Louis, Missouri, United States of America
☯ These authors contributed equally to this work.
‡ MC and ME also contributed equally to this work. RDP and SC also contributed equally to this work.
* salvator@unime.it (SC); dipaolar@unime.it (RDP)
Abstract
Complex regional pain syndrome type 1 (CRPS-I) is a disabling and frequently chronic con-
dition. It involves the extremities and is a frequent consequence of distal tibia and radius
fractures. The inflamed appearance of the affected CRPS-I limb suggests that local produc-
tion of inflammatory mediators may be implicated in the ensuing etiology. A rodent tibia frac-
ture model, characterized by inflammation, chronic unilateral hindlimb warmth, edema,
protein extravasation, allodynia and hyperalgesia resembles the clinical features of patients
with acute CRPS-I. N-palmitoylethanolamine (PEA), a member of the family of naturally-
occurring N-acylethanolamines, is well-known for its ability to modulate inflammatory pro-
cesses and regulate pain sensitivity. However, the large particle size and lipidic nature of
PEA may limit its bioavailability and solubility when given orally. Micronized formulations are
frequently used to enhance the dissolution rate of drug and reduce its variability of absorp-
tion when orally administered. The aim of this study was to assess the effects of a formula-
tion of micronized and ultramicronized PEA (PEA-MPS), given orally in a mouse model of
CRPS-I. CD-1 male mice were subjected to distal tibia fracture and divided into two groups:
control and treated with PEA-MPS (PEA micronized 300 mg/kg and ultramicronized 600
mg/kg). Sensibility to pain was monitored in all mice throughout the course of the experi-
ment. Twenty-eight days after tibia fracture induction animals were sacrificed and biochemi-
cal parameters evaluated. The PEA-MPS-treated group showed an improved healing
process, fracture recovery and fibrosis score. PEA-MPS administration decreased mast cell
density, nerve growth factor, matrix metalloproteinase 9 and cytokine expression. This treat-
ment also reduced (poly-ADP)ribose polymerase activation, peroxynitrite formation and
apoptosis. Our results suggest that PEA-MPS may be a new therapeutic strategy in the
treatment of CRPS-I.
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Introduction
Algodystrophy, or Complex Regional Pain Syndrome type I (CRPS-I), is a painful syndrome
characterized by vasomotor and sensory disturbances, edema and functional impairment. The
first report of Algodystrophy was made by the German surgeon Paul Sundeck more than 110
years ago. He described the case of a patient suffering from “acute inflammatory bone atrophy”
with the accepted clinical signs of inflammation (functio laesa, dolor, tumor, rubor, and calor)
in association with a “patchy” osteoporosis [1]. Even today, a full understanding of the patho-
physiological mechanisms underlying CRPS-I remains elusive. The most convincing patho-
genic hypothesis is a local process of neuroinflammation, perhaps associated with clinical
symptoms occurring in the first stage of the disease (eritrosis, edema, sweating and increased
local temperature) followed later by microvascular damage and microcirculation impairment
observed in most patients (“dystrophic” or “cold” phase) with reduced edema, decreased local
temperature and presence of subcianosis [2].
Neuroinflammation plays an important role in the pathogenesis of both peripheral and
central chronic pain [3, 4]. Resolution of inflammation is controlled by the elaboration of
soluble products [5].Among these numerous lipidic signaling molecules whose role is to
restore tissue homeostasis by suppressing the inflammatory process and by regulating pain
sensitivity through moderating the flow of nociceptive signs to the central nervous system
[6]. The N-acylethanolamines comprise one such family of molecules, whose main members
are N-arachidonoylethanolamine (anandamide) and its congeners N-oleoylethanolamine,
N-stearoylethanolamine and N-palmitoylethanolamine (PEA) [7]. Animal studies demonstrat-
ing the capability of PEA to modulate pain and inflammation propose that this endogenous
fatty acid amide is part of a complex homeostatic system driving the basal threshold of both
pain and inflammation. PEA anti-inflammatory activity has been amply shown in numerous
animal models of inflammation, such as adjuvant-induced arthritis, ischemia reperfusion
injury, idiopatic pulmonary fibrosis, carrageenan-induced paw edema and tuberculin hyper-
sensitivity [8, 9]. PEA, as an endogenous compound, has a double therapeutic effect (that is,
anti-nociceptive and anti-inflammatory) without adverse effects at pharmacologically relevant
doses [10, 11]. Recent report highlights a new PEA potential mechanism of action mediated by
the induction of the CB2 up-regulation [12]. The large particle size and lipidic nature of PEA
limit its solubility and bioavailability. Reports in the literature also highlighted the capability of
other PEA formulations in the possible treatment of abnormal pain induced by several experi-
mental models [13–17]. The micronization technique can be used to achieve microparticles
<10 μm) [18, 19], with increased surface area and rate of dissolution [20], together with a
reduced variability of absorption [21]. In this study, we investigated the effect of oral adminis-
tration of a formulation of micronized and ultramicronized PEA (PEA-MPS) in a model of
CRPS-I.
Materials and methods
Animals
Male adult CD1 mice (25–30 g, Harlan, Italy) were placed in a controlled location and pro-
vided with standard rodent water and chow ad libitum. Mice were accommodated in stainless
steel cages in a room kept at 22 ± 1˚C with a 12-h dark/light cycles. The animals were familiar-
ized to their setting for one week. The study was approved by the University of Messina Review
Board for the care of animals. All animal experiments complied with regulations in USA,
Europe and Italy. All the experiments followed the ARRIVE guidelines.
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Fracture surgery
On day 0, mice were sedated with isoflurane, the right hindlimb enveloped in stockinet (2.5
cm wide) and the distal tibia fractured using a pair of pliers (Visegrip, Petersen Manufactur-
ing) modified with a 3-point jaw. The hindlimb was then covered in casting tape (Delta-Lite,
Johnson & Johnson) to allow the hip, ankle and knee to flex. The cast stretched from the meta-
tarsals to a spica shaped around the abdomen. The cast over the paw only reached to the plan-
tar surface; a space was left over the dorsum of the paw and ankle to avoid constriction when
edema developed post-fracture. The cast was covered in galvanized wire mesh to avoid chew-
ing by the animal. Mice were given buprenorphine (0.03 mg/kg, subcutaneous) and saline
immediately after surgery. At 28 days the mice were anesthetized with isoflurane and the cast
eliminated [22].
Experimental groups
Mice were randomly divided into the following groups (n = 10 for each group):
• Sham + vehicle group: vehicle solution (carboxymethylcellulose 1.5% wt/vol in saline) was
administered orally for 28 days.
• Sham + PEA-MPS group: mice were treated orally daily with PEA-MPS (300 mg/kg PEAm
and 600 mg/kg PEA-um1) for 28 days.
• Fracture + vehicle group: vehicle solution (carboxymethylcellulose 1.5% wt/vol in saline) was
administered orally daily 1 h after surgery for 28 days.
• Fracture + PEA-MPS group: mice were treated orally daily with PEA-MPS (300 mg/kg
PEAm and 600 mg/Kg PEA-um1) 1 h after surgery for 28 days.
The dose of PEA-MPS was chosen based on previous experiments [23].
In this study, we have demonstrated the beneficial effects of PEA in reducing edema forma-
tion and thermal hyperalgesia in carrageenan-induced inflammation in the rat paw. These
results show the differential effects exerted on the degree of inflammation by micronized PEA-
m and ultramicronized PEA-um, vs nonmicronized PeaPure.
We have done the calculation to know the dose of PEA-MPS that should be assumed by
human. According to the formula applied for the conversion from animal to human, the dose
of PEA-MPS that should be taken would be about 170,26 mg/Kg (56,75 mg/Kg PEAm and
113,51 mg/Kg PEA-um1), reasonably low [24]. Human Equivalent Dose PEA-MPS (mg/kg) =
(300x[7/37]) + (600x[7/37]) = 170,26 mg/Kg.
The minimum number of animals for each group was calculated using the statistical test a
priori power analyzes of the G-power software. This statistical test provides an efficient
method for determining the sample size necessary to perform the experiment before the exper-
iment the same is actually conducted.
Behavioral measurements
Three tests were employed to calculate pain behavior: mechanical nociception measured by
the withdrawal response to von Frey filament application, thermal nociception measured by
the withdrawal response to thermal stimulus (hot plate test), and subjective pain assessed
using a pain rating scale [25].
Mechanical nociception. To measure mechanical allodynia in the rats an up–down von
Frey testing paradigm was used. Mice were located beneath a clear plastic cylinder (20 cm in
diameter) on an elevated mesh floor and acclimatated for 15 min. Withdrawal responses to
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mechanical stimulation were assessed using calibrated von Frey filaments placed from under-
neath the chamber through openings in the mesh floor against approximately the middle of
the hind paw plantar skin at the fractured side. The fibers were presented according to the up–
down method of Dixon to generate six responses in the immediate vicinity of the 50% thresh-
old. The filament was pressed until it slightly curved and then it was left in that position for 6 s.
Each filament was applied once, beginning with 0.008 g and continuing until a withdrawal
response was considered positive. After a pause of 5–10 min, each filament was again used
once, beginning with 0.008 g until a withdrawal response was achieved. This was replicated a
third time 5–10 min later. The withdrawal threshold was considered the lowest force produc-
ing a response from the three tests [26].
Thermal nociception. Thermal nociception was assessed by a modified hot plate test [27].
Thermal nociception (thermal latency) was reflected by the time that a mouse would leave its
hind paw on a hot plate at 52˚C. The paw was shifted from the plate by the investigator after a
maximal time of 12 s to avoid thermal hyperalgesia and injury. This test was replicated three
times.
Subjective pain scale. A subjective pain rating scale (0–5) was utilized to quantify the
pain. Zero is normal, 1 is crimping of the toes, 2 is evasion of the paw, 3 is limited weight bear-
ing, 4 is non–weight bearing, and 5 is evasion of any contact with the hind limb.
Radiographic analysis
Lateral radiographs of the tibiae from mice were taken using a X-ray apparatus (FX Pro Bru-
cher, Italy). Mineralized callus realization and bony association at the fracture site were evalu-
ated. Callus total volume (TV) assessed the volume of recently formed tissues and low-density
bone volume (BVl) assessed the volume of recently formed mineralized tissue in callus. BV1
and TV were both calculated by a decrease of the volume in fractured tibia with the volume of
the contralateral bone.
Histological analysis
On day 28 after fracture, mice were sacrificed by anaesthetic overdose. Tibiae were collected
and post-fixed in 10% formalin and decalcified in EDTA for 24 h. The specimens were then
embedded in paraffin, 5 μm sections prepared, stained with hematoxylin/eosin, and analysed
by histomorphometry [28–30]. Contrast and illumination were established by examining the
most intensely labelled pixels and applying backgrounds that allowed clear image of structural
details while keeping the highest pixel intensities close to 200. The same backgrounds were
used for all images acquired from the other samples that had been managed in parallel. Digital
images were collected and figure montages arranged using Adobe Photoshop CS6 (Adobe Sys-
tems; Milan Italy).
Masson trichrome, safranin O/fast green and toluidine blue staining
The degree of fibrosis was evaluated according to the manufacturer’s protocol (Bio-Optica,
Italy, Milan), with tissue sections being stained with Masson trichrome. In order to evaluate
the presence of osteoclasts and osteoblasts, samples were stained with safranin O/fast green,
again according to the manufacturer’s protocol (Bio-Optica, Italy, Milan). Tissue sections
were also stained with toluidine blue to evaluate the number and degranulation of mast cells,
together with histopathological analysis of the callus and cartilage volumes. Sections were
deparaffinised in xylene and dehydrated by a graded series of ethanols, 4 min in each. The sec-
tions were next placed in water for 5 min, transferred to toluidine blue for 4 min and then blot-
ted carefully. Sections were next placed in absolute alcohol for 1 min, then in xylene, followed
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by mounting on a glass slide using Eukitt (Bio-Optica, Italy, Milan). Cartilage was stained blue
with mast cells coloured purple. The mast cell count and cartilage analysis were performed on
each slide using an Axiovision Zeiss (Milan, Italy) microscope.
Immunohistochemical localization of nerve growth factor (NGF), matrix
metalloproteinase (MMP)9, tumor necrosis factor alpha (TNF-α),
interleukin-1beta (IL-1β), nitrotyrosine, poly(ADP-ribose) (PAR), Bax
and Bcl-2
At 28 days post-surgery, tibia fractures were fixed in PBS-buffered formaldehyde 10% (w/v)
and embedded in paraffin. Seven μM sections from each tissue were prepared. After deparaffi-
nization, endogenous peroxidase was quenched with 0.3% (v/v) hydrogen peroxide/60% water
for 30 min. Tissue was permeabilized with 0.1% (w/v) Triton X-100 in PBS for 20 min. Slides
were incubated in 2% normal goat serum in PBS to block non-specific binding. Endogenous
avidin and biotin binding sites were blocked vy sequential incubation with avidin and biotin
(Vector Laboratories, Burlingame, CA) for 15 min. Sections were then incubated overnight
with one of the following primary antibodies: anti-NGF (E-12: sc-365944, 1:460 in PBS, Santa
Cruz Biotechnology), anti-MMP9 (C-20: sc-6840, 1:360 in PBS, Santa Cruz Biotechnology),
anti-TNF-α (H-156: sc-8301, 1:460 in PBS, Santa Cruz Biotechnology), anti-IL-1β (H-153: sc-
7884, 1:460 in PBS, Santa Cruz Biotechnology), anti-nitrotyrosine (1:460 in PBS, Millipore,
06–284), anti-PAR (H-250: sc-7150, 1:560 in PBS, Santa Cruz Biotechnology), anti-Bax(P-19:
sc-526, 1:460 in PBS, Santa Cruz Biotechnology) or anti-Bcl-2 (N-19: sc-492, 1:360 in PBS,
Santa Cruz Biotechnology). Sections were washed with PBS and incubated with secondary
antibody. Specific labeling was visualized with a biotin-conjugated goat anti-rabbit IgG and
avidin–biotin peroxidase complex (Vector Laboratories, Burlingame, CA). Immunohisto-
chemical images were taken using a Zeiss microscope and Axio Vision software. For graphic
display of densitometric analyses, the intensity of positive staining (brown staining) was mea-
sured by computer-assisted color image analysis (Leica QWin V3, UK). The percentage area of
immunoreactivity (determined by the number of positive pixels) was expressed as a percent of
total tissue area (red staining). Contrast and illumination were established by examining the
most intensely labelled pixels and applying backgrounds that allowed clear image of structural
details while keeping the highest pixel intensities close to 200. The same backgrounds were
used for all images acquired from the other samples that had been managed in parallel. Digital
images were collected and figure montages arranged using Adobe Photoshop CS6 (Adobe Sys-
tems; Milan Italy).
Materials
All compounds were purchase from Sigma-Aldrich (Milan, Italy). All chemicals were of the
highest grade available. All stock solutions were prepared in non-pyrogenic saline (0.9% NaCl;
Baxter, Italy). PEA-MPS was kindly provided by Epitech Group SpA (Saccolongo, Italy).
Statistical analysis
All values are represented as mean±standard error of the mean (SEM) with ‘n’ representing
the number of experimental observations per cohort. In experiments involving histology, the
figures shown are representative of at least three experiments performed on different days.
The results were analyzed by one-way ANOVA followed by a Bonferroni post-hoc test for mul-
tiple comparisons. All statistical analyses were carried out using GraphPad Prism1 Version
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5.00 statistical software. A p-value less than 0.05 was considered significant. p<0.05 vs. sham,
˚ p<0.05 vs vehicle.
Results
Effect of PEA-MPS treatment on fracture-induced nociceptive behavior
Mechanical nociception, thermal nociception and subjective pain were significantly modified
by treatment with PEA-MPS as compared to the vehicle-treated group. Mechanical hyperalge-
sia and allodynia were calculated at the hind paw by score values measured from the von Frey
filament test. As shown in Fig 1A, withdrawal response to mechanical stimulus increased in
PEA-MPS treated-mice, indicating a decreased nociception, compared to vehicle-treated mice.
The same pattern was observed in the hot plate test for thermal nociception (Fig 1B), with
response latency in vehicle treated-mice showing an increased nociception that was signifi-
cantly reduced in PEA-MPS-treated mice in compared to sham mice. The subjective pain scale
(Fig 1C) was significantly decreased in PEA-MPS treated-mice compared to vehicle treated-
mice, while sham mice remained unchanged.
Effect of PEA-MPS treatment on fracture healing process
To verify correct fracture execution and to determine the effect of PEA-MPS treatment on
fracture repair, mice were subjected to X-ray analysis. No difference between vehicle-treated
mice (Fig 2B and 2F) and PEA-MPS-treated mice (Fig 2C and 2F) was noted immediately
after the fracture (day 0). At 28 days post-surgery the callus area was significantly larger in
PEA-MPS-treated mice (Fig 2E and 2F) compared to vehicle-treated animals (Fig 2D and 2F).
Effect of PEA-MPS treatment on facture recovery and fibrosis
Twenty-eight days after surgery mice were sacrificed and longitudinal sections of tibia stained
with hematoxylin/eosin. Tissues from PEA-MPS-treated mice (Fig 3B and 3G) showed more
callus formation and new woven bone with respect to vehicle-treated mice (Fig 3C and 3G). At
this time the degree of fibrosis, assessed by Masson trichrome staining, demonstrated a blue
fibrotic area that was larger in the PEA-MPS group (Fig 3F and 3H) compared to the vehicle
group (Fig 3E and 3H).
Effect of PEA-MPS treatment on mast cell density and NGF expression
Toluidine blue staining was used to assess mast cell number. Mast cell number was increased
following distal tibia fracture in vehicle-treated mice (Fig 4B and 4G) compared to sham ani-
mals (Fig 4A and 4G). In contrast, PEA-MPS treatment significantly reduced mast cell number
(Fig 4B and 4G). Immunohistochemical analysis of tissues collected from vehicle-treated mice
showed an increase of NGF staining (Fig 4E and 4H) which was lower in PEA-MPS-treated
mice (Fig 4F and 4H). Sham-treated mice did not show any significant NGF immnostaining
(Fig 4D and 4H).
Effect of PEA-MPS treatment on MMP9 expression and cartilage
formation
Twenty-eight days after surgery MMP9 expression was analysed in tissues collected from
sham, vehicle and PEA-MPS-treated mice. MMP9 expression was up-regulated in PEA-MPS-
treated mice (Fig 5C and 5G), compared to vehicle-treated mice (Fig 5B and 5G). Sham-
treated mice showed a basal expression of MMP9 (Fig 5A and 5G). PEA-MPS-treated mice
New formulation of micronized and ultramicronized N-palmitoylethanolamine and complex regional pain syndrome
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Fig 1. Efficacy of PEA-MPS on fracture-induced nociceptive behaviour. Twenty-eight days after fracture
three tests were used to assess pain behaviour. (A) Withdrawal response to von Frey filaments-induced
mechanical hyperalgesia in the fractured hind paw. PEA-MPS treatment increased the withdrawal response.
(B) Thermal nociception was assessed by a modified hot plate test. PEA-MPS treated-mice showed
increased withdrawal latency compared to vehicle treated-mice. (C) Subjective pain scale evaluating pain in
the fractured hind paw. PEA-MPS treatment decreased pain compared to vehicle treated-mice. A p-value less
than 0.05 was considered significant. *p<0.05 vs. sham, ˚ p<0.05 vs vehicle.
https://doi.org/10.1371/journal.pone.0178553.g001
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Fig 2. Efficacy of PEA-MPS on fracture healing process. Mice with tibia fracture were treated orally with
vehicle (B) or PEA-MPS (C). Twenty-eight days later PEA-MPS treatment accelerated the fracture healing
process (E) compared to vehicle-treated mice (D). PEA-MPS also stimulated callus bridging and increased
bone density (F). A p-value less than 0.05 was considered significant. *p<0.05 vs. sham, ˚ p<0.05 vs vehicle.
https://doi.org/10.1371/journal.pone.0178553.g002
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Fig 3. Efficacy of PEA-MPS on facture recovery and fibrosis. Twenty-eight days after fracture histological examination
showed more callus formation and new woven bone in PEA-MPS-treated mice (B and G, and Figure b in S1 File) compared to
vehicle-treated animals (C and G, and Figure c in S1 File). Masson trichrome staining demonstrated an increased fibrotic area
in the PEA-MPS group (F and H, and Figure f in S1 File) compared to the vehicle group (E and H, and Figure e in S1 File). A p-
value less than 0.05 was considered significant. *p<0.05 vs. sham, ˚ p<0.05 vs vehicle.
https://doi.org/10.1371/journal.pone.0178553.g003
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Fig 4. Efficacy of PEA-MPS on mast cell density and NGF expression. Mast cell number was increased in vehicle-treated
mice (B and G, and Figure b in S2 File) compared to the sham group (A and G, and Figure a in S2 File). PEA-MPS treatment
significantly reduced the tibia fracture-induced increase in mast cell number (B and G, and Figure b in S2 File). Tissue from
vehicle-treated mice showed an increased NGF immunostaining (E and H, and Figure e in S2 File) compared to sham-treated
mice (D and H, and Figure d in S2 File) which was reduced by PEA-MPS treatment (F and H, and Figure f in S2 File). A p-
value less than 0.05 was considered significant. *p<0.05 vs. sham, ˚ p<0.05 vs vehicle.
https://doi.org/10.1371/journal.pone.0178553.g004
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Fig 5. Efficacy of PEA-MPS on MMP9 expression and cartilage formation. MMP9 expression was analyzed
immunohistochemically 28 days after surgery. PEA-MPS-treated mice showed an increased staining (C and G, and Figure c in
S3 File) compared to vehicle-treated mice (B and G), while tissue from sham-treated mice showed basal MMP9 expression (A
and G, and Figure a in S3 File). Toluidine blue staining demonstrated a significantly greater amount of cartilage area in
PEA-MPS-treated mice (F and H, and Figure f in S3 File) compared to the vehicle group (E and G, and Figure e in S3 File). A
p-value less than 0.05 was considered significant. *p<0.05 vs. sham, ˚ p<0.05 vs vehicle.
https://doi.org/10.1371/journal.pone.0178553.g005
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had a significantly lower amount of cartilage area (Fig 5F and 5H) as assessed by toluidine blue
staining, compared to vehicle-treated mice (Fig 5E and 5G).
Effect of PEA-MPS treatment on osteoclasts on tissue sections
Safranin O/fast green staining was utilized to evaluate the impact of PEA-MPS treatment on
skeletal cell differentiation 28 days after fracture. Vehicle-treated mice displayed greater endo-
chondral ossification (Fig 6B and 6D) compared to sham-treated mice (Fig 6A and 6D).
PEA-MPS reduced the presence of osteoblasts in the fracture lesion (Fig 6C and 6D).
Effect of PEA-MPS treatment on TNF-α and IL-1β expression
At 28 days post-surgery tissues from vehicle-treated mice exhibited a substantial increase in
TNF-α immunostaining (Fig 7B and 7G) and PEA-MPS treatment reduced this staining (Fig
7C and 7G). Moreover, mice subjected to distal tibia facture had increased immunoreactivity
for IL-1β (Fig 7E and 7H) which was reduced by PEA-MPS treatment (Fig 7F and 7H). Sham-
treated mice were immunonegative for both markers (Fig 7A, 7D, 7G and 7H).
Effect of PEA-MPS treatment on nitrotyrosine and PAR formation
The presence of nitrogen derivatives in animals at 28 days post-distal tibia fracture was
assessed immunohistochemically as nitrotyrosine, a specific marker of nitrosative stress. Tis-
sue from vehicle-treated mice exhibited positive nitrotyrosine staining (Fig 8B and 8G), which
was significantly decreased by PEA-MPS treatment (Fig 8C and 8G). To examine poly(ADP-
ribose)polymerase (PARP) activation, PAR development was examined immunohistochemi-
cally. PAR staining was significantly increased in the nuclei of inflammatory cells collected
from vehicle-treated mice (Fig 8E and 8H), and PEA-MPS treatment markedly reduced this
staining (Fig 8F and 8H). Sham-treated mice did not show any positive staining (Fig 8A, 8D,
8G and 8H).
Effects of PEA-MPS treatment on Bax and Bcl-2 expression
In order to test whether PEA-MPS treatment was able to modulate tibia distal fracture-induced
apoptosis, we examined the expression of both the pro-apoptotic Bax and the anti-apoptotic
Bcl-2 proteins. Vehicle-treated mice showed increased Bax staining (Fig 9B and 9G) compared
to sham-treated mice (Fig 9A and 9G). PEA-MPS treatment decreased this staining (Fig 9C
and 9G). In addition, sham-treated mice exhibited positive Bcl-2 staining (Fig 9D and 9H)
compared to vehicle-treated animals (Fig 9E and 9H). Furthermore, PEA-MPS treatment
reverted the inhibitory action of distal tibia fracture on Bcl-2 expression (Fig 9F and 9H).
Discussion
The present study explored the effect of PEA-MPS treatment on CRPS-I in mice. The develop-
ment of animal models displaying clinical signs substantially comparable to human CRPS-I
with the same evolution as frequently seen in the clinic has been an area of active examination.
Distal tibia fracture is the most widely used mouse model of CRPS-I-associated chronic pain
due to its ability to increase local release of cytokines and pro-inflammatory neuropeptides
[31]. Such bone fracture may be the event that triggers and maintains the initial phases of the
pathology, causing allodynia and hyperalgesia [22]. PEA-MPS treatment reduced the mechani-
cal hyperalgesia and thermal nociception. Our results revealed also an action of oral PEA-MPS
in the process of fracture healing. These animals showed a decreased inflammatory response
during the early phase and an increase in the degree of fibrosis, cartilaginous callus formation
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and woven bone remodelling during the late phase. In the primary stage of the inflammatory
process, mast cell accumulation in injured tissues plays a central role [32]. In the skin of the
affected extremity CRPS-I patients show increased tryptase, suggesting an increase in mast cell
accumulation and degranulation [33]. Because mast cells release a number of inflammatory
mediators such as NGF [34] in injured tissues, we hypothesized that mast cell degranulation
is involved in the nociceptive sensitization in this tibia fracture model of CRPS-I. PEA-MPS
oral treatment reduced mast cells and, in parallel, significantly limited NGF expression in the
inflamed tissue.
MMPs have important roles in bone repair and development, and participate in the interac-
tion between skeletal progenitors and inflammatory cells [29, 35]. MMP9 participates also dur-
ing the inflammatory phases of repair [36]. PEA-MPS oral administration significantly up-
regulated MMP9 expression compared to vehicle-treated mice. MMP9 is expressed both by
osteoclasts and bone marrow-derived myeloid cells, which are involved in extracellular matrix
remodelling during bone repair [37]. PEA-MPS treatment clearly accelerated endochondral
Fig 6. Efficacy of PEA-MPS on osteoclasts on tissue sections. Safranin O/fast green staining was used to evaluate skeletal cell
differentiation and callus formation. PEA-MPS treatment accelerated osteogenesis and bone formation in the callus (C and D, and
Figure c in S4 File) compared to the vehicle-treated mice (B and D, and Figure b in S4 File). A p-value less than 0.05 was considered
significant. *p<0.05 vs. sham, ˚ p<0.05 vs vehicle.
https://doi.org/10.1371/journal.pone.0178553.g006
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Fig 7. Efficacy of PEA-MPS on TNF-α and IL-1β expression. Twenty-eight days after surgery tissue taken from vehicle-
treated mice displayed a substantial increase in TNF-α immunostaining (B and G, and Figure b in S5 File), compared to sham-
treated mice(A and G, and Figure a in S5 File). At this time also IL-1β staining was increased (E and H, and Figure e in S5 File)
with respect to sham-treated mice (D and H, and Figure d in S5 File). PEA-MPS treatment reduced staining for both markers
(C, F and G, H, and Figure c and f in S5 File). A p-value less than 0.05 was considered significant. *p<0.05 vs. sham, ˚ p<0.05
vs vehicle.
https://doi.org/10.1371/journal.pone.0178553.g007
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Fig 8. Efficacy of PEA-MPS on nitrotyrosine and PAR formation. Samples from vehicle-treated mice displayed positive
nitrotyrosine staining (B and G, and Figure b in S6 File) and PEA-MPS treatment significantly reduced this effect (C and G, and
Figure c in S6 File). Nuclear PAR staining was notably increased in inflammatory cells of vehicle mice (E and H, and Figure e in
S6 File), which was reduced by PEA-MPS treatment (F and H, and Figure f in S6 File). Sham-treated mice failed to show
positive staining (A, D for nitrotyrosine and G, H for PAR, respectively, Figure a and d in S6 File). A p-value less than 0.05 was
considered significant. *p<0.05 vs. sham, ˚ p<0.05 vs vehicle.
https://doi.org/10.1371/journal.pone.0178553.g008
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Fig 9. Efficacy of PEA-MPS on Bax and Bcl-2 expression. Twenty-eight days after surgery, tissues from vehicle-treated
mice showed increased staining for Bax (B and G, and Figure b in S7 File) compared to sham mice (A and G, and Figure a in S7
File). PEA-MPS treatment decreased this staining (C and G, and Figure c in S7 File). Sham-treated mice exhibited positive Bcl-
2 staining (D and H, and Figure d in S7 File) compared to vehicle-treated animals (E and H, and Figure e in S7 File). Moreover,
PEA-MPS treatment reverted the inhibitory action of distal tibia fracture on Bcl-2 protein expression (F and H, and Figure f in S7
File). A p-value less than 0.05 was considered significant. *p<0.05 vs. sham, ˚ p<0.05 vs vehicle.
https://doi.org/10.1371/journal.pone.0178553.g009
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ossification, whereas numerous uncalcified chondrocytes–implicated in delayed healing—per-
sisted at the fracture site in untreated mice.
In the first phase of fracture repair, primary haemorrhage within fracture sites progresses
into a hematoma, with infiltrating inflammatory cells (including macrophages) [38]. This in-
filtrate induces the activation of inflammatory cascades through the secretion of numerous
cytokines. Macrophages produce pro-inflammatory cytokines such as TNF-α and IL-1 [39].
PEA-MPS treatment reduced up-regulation of these two cytokines. In the cascade of events
which accompany the later phases of CRPS-I, metabolic alterations due to a disturbed capillary
exchange exacerbate and maintain the clinical features of CRPS-I. In this setting, up-regulation
of oxygen free radicals such as superoxide anion and peroxynitrite support the inflammatory
process [40]. These radicals cause oxidization of sulfhydryl groups, lipid peroxidation and
nitration of tyrosine residues. Lipid peroxidation and nitrotyrosine expression were elevated
in our distal tibia fracture mice, and treatment with PEA-MPS significantly reduced nitrotyro-
sine immunostaining. Peroxynitrite can also activate the DNA repair enzyme PARP, which
synthesizes chains of ADP-ribose in reply to single-strand DNA breaks. NAD+ is required for
this reaction, and hyper-activation of PARP can reduce cellular reserves of NAD+ and lead to
ATP depletion, ultimately resulting in cellular dysfunction and death. In the present study,
PEA-MPS treatment decreased PARP activity. Finally, tissue apoptosis may serve as a marker
for CRPS-I [41, 42]. Our data show that PEA-MPS treatment reduced tibia fracture-induced
Bax expression and increased Bcl-2 expression that was reduced in tibia fracture mice.
Conclusions
Collectively, the findings described here demonstrate that 28 days after tibia fracture induction
PEA-MPS treatment, by attenuating the inflammatory response, allodynia and hyperalgesia,
may be an innovative pharmacological approach for treatment of CRPS-I.
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